On November 7, 2020, Suzhou National Hi-Tech District（hereinafter referred to as ”SND”） signed agreement with Mednovo Group Co., LTD.

Mednovo has included a number of projects such as TAVR system, TMVr and TTVr system and formed industrialization in SND.

In the future, the Group will expand its manufacturing system in the mode of "self-R&D + acquisition + equity investment". To accurately explore high-tech products at home and abroad, and achieve industrialization of these new projects, so as to inject new momentum into the development of medical device industry in SND.

Wang Mou，deputy director of SND management committee, stated “as a well-known large group in medical and health industry at home and abroad, Mednovo has strong competitive advantages in the field of minimally invasive intervention, for the fact that it engages in whole industrial chain, from upstream-investment and financing, to midstream- R&D and manufacturing, and to downstream-sales and services”.

“I believe that Mednovo will seize the moment to build up its momentum by accurate pointing at advanced technologies and products at home and abroad, and grow bigger and stronger together with SND.

He added , SND will further focus on the whole process, from R&D, manufacturing & production till market launch by introducing and cultivating more upstream and downstream supporting service providers, so that one can find everything they need within SND.

Li Peishang , Chairman&CEO of Mednovo group, said “we have been looking for a suitable industrial base all over China since the beginning of this year. Thanks to the strong recommendation of a peer company in SND, he brings our attention here.”

“As one of the national key medical device industry innovation base, SND has superior geographical location, relatively mature environment, more importantly, it has a professional team providing great service, their pragmatic, rigorous, efficient work style and their professional spirit deeply moved us. We are sure that we will not regret our choice.”

Zhang Fengting , chairman of Suzhou Betong Medical, said “As a practitioner in the medical industry, I have witnessed the precise policy, intensive cultivation and vigorous development of SND in years in the medical device industry. With the jointly cooperation with SND, Mednovo will certainly take root and prospers in this ’paradise of entrepreneurs.”

Liu Jian , president of Qilun Venture Capital , said “As a participant in the establishment of Mednovo, I have witnessed its rapid growth in the past 9 years. Today, Mednovo expands the industrialization system in the field of minimally invasive intervention with the mode of ‘self-R&D + acquisition + equity investment’, which will definitely become a new model of innovation and entrepreneurship in the field of minimally invasive intervention industrialization in China, and also a new highlight in the economic development of SND.”

According to the agreement, Mednovo Group Co., Ltd. will be settled in the Jiangsu Medical Device Science and Technology Industrial Park, and purchase land to build its own carrier project, which is expected to invest more than 300 million RMB in phaseⅠ, with a total investment of more than 1 billion RMB. TAVR, TMVr and TTVr system; thrombectomy system on Aorta and branch arteries, neruo-intervention, assisted reproduction and other projects will be put into practice and form industrialization in SND.

In the future, the Group will also expand M&P system with the mode of "self-R&D + acquisition + equity investment", accurately explore state of the art technologies and products internationally, and realize implementation and industrialization of new projects.

Mednovo Group was founded in 2011, is a diversified large group covers R&D, production, sales, investment & financing, focusing on the medical and health industry, committed to building a whole industry chain, covering upstream-investment & financing, midstream- R&D and manufacturing, and downstream-sales & services in the "minimally invasive intervention" field.

The group is engaged in Class II/III minimally invasive interventional medical devices. Mednovo’s currently has nearly 500 sales rep, with 40 branches and 25 offices, its products cover 15 departments, we represent a total of 28 brands and have 76 product lines, and rank the 1st in sales revenue, personnel size, network coverage, and the number of professional clinical departments served.

The group achieved sales of 2 billion yuan in 2018, 2.6 billion yuan in 2019, and is expected to exceed 3.4 billion yuan in 2020, with an annual growth rate of over 30%.

As the only one that focuses on supporting the development of the medical device industry in the strategic layout of "one district, one industry" in Jiangsu Province, SND grabs the new air outlet for the development of medical devices, closely follows the positioning of one of the "two cores" of Suzhou biomedical industry, and strives to build the most perfect medical device "industrial chain".